{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:05:15Z","timestamp":1787954715130,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Spirita Oncology, LLC","award":["na"],"award-info":[{"award-number":["na"]}]},{"name":"Spirita Oncology, LLC","award":["na"],"award-info":[{"award-number":["na"]}]},{"DOI":"10.13039\/100019915","name":"Helios Education Foundation","doi-asserted-by":"crossref","award":["na"],"award-info":[{"award-number":["na"]}],"id":[{"id":"10.13039\/100019915","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006755","name":"School of Life Sciences, Arizona State University","doi-asserted-by":"publisher","award":["Undergraduate Research Program"],"award-info":[{"award-number":["Undergraduate Research Program"]}],"id":[{"id":"10.13039\/100006755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,8,15]]},"DOI":"10.1007\/s10637-018-0668-8","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T01:07:33Z","timestamp":1538096853000},"page":"636-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases"],"prefix":"10.1007","volume":"37","author":[{"given":"Hani M.","family":"Babiker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Byron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P. D.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautham","family":"Gampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Vondrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Cuyugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Tibes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Marceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"Paradiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie S.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Cridebring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Carpten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"issue":"1","key":"668_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"668_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696. https:\/\/doi.org\/10.1002\/cncr.25634","journal-title":"Cancer"},{"key":"668_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N (2012) The role of BRAF V600 mutation in melanoma. J Transl Med 10:85. https:\/\/doi.org\/10.1186\/1479-5876-10-85","journal-title":"J Transl Med"},{"key":"668_CR4","doi-asserted-by":"publisher","first-page":"851387","DOI":"10.1155\/2015\/851387","volume":"2015","author":"A Niezgoda","year":"2015","unstructured":"Niezgoda A, Niezgoda P, Czajkowski R (2015) Novel approaches to treatment of advanced melanoma: a review on targeted therapy and immunotherapy. Biomed Res Int 2015:851387\u2013851316. https:\/\/doi.org\/10.1155\/2015\/851387","journal-title":"Biomed Res Int"},{"issue":"11","key":"668_CR5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087\u20131095. https:\/\/doi.org\/10.1016\/S1470-2045(12)70431-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"668_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","volume":"50","author":"R Dummer","year":"2014","unstructured":"Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50(3):611\u2013621. https:\/\/doi.org\/10.1016\/j.ejca.2013.11.002","journal-title":"Eur J Cancer"},{"issue":"3","key":"668_CR7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/annonc\/mdw641","volume":"28","author":"GA McArthur","year":"2017","unstructured":"McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K (2017) Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol 28(3):634\u2013641. https:\/\/doi.org\/10.1093\/annonc\/mdw641","journal-title":"Ann Oncol"},{"issue":"7","key":"668_CR8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Marquez-Rodas I, Del Vecchio M, Lebbe C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873. https:\/\/doi.org\/10.1016\/S1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"issue":"22","key":"668_CR9","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","volume":"29","author":"N Wagle","year":"2011","unstructured":"Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29(22):3085\u20133096. https:\/\/doi.org\/10.1200\/JCO.2010.33.2312","journal-title":"J Clin Oncol"},{"issue":"12","key":"668_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","volume":"13","author":"AA Samatar","year":"2014","unstructured":"Samatar AA, Poulikakos PI (2014) Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 13(12):928\u2013942. https:\/\/doi.org\/10.1038\/nrd4281","journal-title":"Nat Rev Drug Discov"},{"issue":"15_suppl","key":"668_CR11","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","volume":"35","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, PAJ F, Algazi AP, Hamid O, Hodi FS, Moschos SJ, Khushalani KI, Gonzalez R, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini AA, Jiang J, Avila A, Demelo S, Margolin KA (2017) Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J Clin Oncol 35(15_suppl):9507. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9507","journal-title":"J Clin Oncol"},{"issue":"5","key":"668_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19(5):672\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(18)30139-6","journal-title":"Lancet Oncol"},{"issue":"5","key":"668_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459\u2013465. https:\/\/doi.org\/10.1016\/S1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"issue":"7","key":"668_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976\u2013983. https:\/\/doi.org\/10.1016\/S1470-2045(16)30053-5","journal-title":"Lancet Oncol"},{"key":"668_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.phrs.2017.06.008","volume":"123","author":"G Gampa","year":"2017","unstructured":"Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF (2017) Drug delivery to melanoma brain metastases: can current challenges lead to new opportunities? Pharmacol Res 123:10\u201325. https:\/\/doi.org\/10.1016\/j.phrs.2017.06.008","journal-title":"Pharmacol Res"},{"key":"668_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1476-4598-11-75","volume":"11","author":"SA Byron","year":"2012","unstructured":"Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75. https:\/\/doi.org\/10.1186\/1476-4598-11-75","journal-title":"Mol Cancer"},{"issue":"5","key":"668_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1124\/dmd.117.079194","volume":"46","author":"G Gampa","year":"2018","unstructured":"Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF (2018) Brain distribution of a novel MEK inhibitor E6201: implications in the treatment of melanoma brain metastases. Drug Metab Dispos 46(5):658\u2013666. https:\/\/doi.org\/10.1124\/dmd.117.079194","journal-title":"Drug Metab Dispos"},{"key":"668_CR18","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-018-0099-5","volume":"118","author":"R Tibes","year":"2018","unstructured":"Tibes R, Borad MJ, Dutcus CE, Reyderman L, Feit K, Eisen A, Verbel DA, Von Hoff DD (2018) Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. Br J Cancer 118:1580\u20131585. https:\/\/doi.org\/10.1038\/s41416-018-0099-5","journal-title":"Br J Cancer"},{"issue":"4","key":"668_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1101\/gr.213348.116","volume":"27","author":"WS Liang","year":"2017","unstructured":"Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J (2017) Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res 27(4):524\u2013532. https:\/\/doi.org\/10.1101\/gr.213348.116","journal-title":"Genome Res"},{"issue":"1","key":"668_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/jpet.110.167601","volume":"334","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334(1):147\u2013155. https:\/\/doi.org\/10.1124\/jpet.110.167601","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"668_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, Schultz N, Taylor BS (2016) Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34(2):155\u2013163. https:\/\/doi.org\/10.1038\/nbt.3391","journal-title":"Nat Biotechnol"},{"key":"668_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1515-3","volume":"15","author":"Z Helias-Rodzewicz","year":"2015","unstructured":"Helias-Rodzewicz Z, Funck-Brentano E, Baudoux L, Jung CK, Zimmermann U, Marin C, Clerici T, Le Gall C, Peschaud F, Taly V, Saiag P, Emile JF (2015) Variations of BRAF mutant allele percentage in melanomas. BMC Cancer 15:497. https:\/\/doi.org\/10.1186\/s12885-015-1515-3","journal-title":"BMC Cancer"},{"issue":"4","key":"668_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/CMR.0000000000000088","volume":"24","author":"C Lebbe","year":"2014","unstructured":"Lebbe C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S (2014) BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma. Melanoma Res 24(4):415\u2013418. https:\/\/doi.org\/10.1097\/CMR.0000000000000088","journal-title":"Melanoma Res"},{"issue":"9","key":"668_CR24","doi-asserted-by":"publisher","first-page":"e0138210","DOI":"10.1371\/journal.pone.0138210","volume":"10","author":"BJ Capaldo","year":"2015","unstructured":"Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S (2015) Systems analysis of adaptive responses to MAP kinase pathway blockade in BRAF mutant melanoma. PLoS One 10(9):e0138210. https:\/\/doi.org\/10.1371\/journal.pone.0138210","journal-title":"PLoS One"},{"key":"668_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1479-5876-8-39","volume":"8","author":"JN Sondergaard","year":"2010","unstructured":"Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A (2010) Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39. https:\/\/doi.org\/10.1186\/1479-5876-8-39","journal-title":"J Transl Med"},{"issue":"4","key":"668_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/1535-7163.MCT-13-0667","volume":"13","author":"Y Narita","year":"2014","unstructured":"Narita Y, Okamoto K, Kawada MI, Takase K, Minoshima Y, Kodama K, Iwata M, Miyamoto N, Sawada K (2014) Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. Mol Cancer Ther 13(4):823\u2013832. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0667","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"668_CR27","doi-asserted-by":"publisher","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","volume":"59","author":"TP Heffron","year":"2016","unstructured":"Heffron TP (2016) Small molecule kinase inhibitors for the treatment of brain cancer. J Med Chem 59(22):10030\u201310066. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00618","journal-title":"J Med Chem"},{"issue":"11","key":"668_CR28","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1021\/mp500435s","volume":"11","author":"EF Choo","year":"2014","unstructured":"Choo EF, Ly J, Chan J, Shahidi-Latham SK, Messick K, Plise E, Quiason CM, Yang L (2014) Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib. Mol Pharm 11(11):4199\u20134207. https:\/\/doi.org\/10.1021\/mp500435s","journal-title":"Mol Pharm"},{"issue":"8","key":"668_CR29","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1124\/dmd.114.058339","volume":"42","author":"S Vaidhyanathan","year":"2014","unstructured":"Vaidhyanathan S, Mittapalli RK, Sarkaria JN, Elmquist WF (2014) Factors influencing the CNS distribution of a novel MEK-1\/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos 42(8):1292\u20131300. https:\/\/doi.org\/10.1124\/dmd.114.058339","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"668_CR30","doi-asserted-by":"publisher","first-page":"e92146","DOI":"10.1371\/journal.pone.0092146","volume":"9","author":"JC Uitdehaag","year":"2014","unstructured":"Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, de Man J, Tanizawa Y, Kawase Y, Yoshino K, Buijsman RC, Zaman GJ (2014) Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One 9(3):e92146. https:\/\/doi.org\/10.1371\/journal.pone.0092146","journal-title":"PLoS One"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0668-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:32:59Z","timestamp":1678559579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0668-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,15]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0668-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]},"assertion":[{"value":"16 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Thomas J. Myers and Linda J. Paradiso are employees of Spirita Oncology, LLC. Daniel D. Von Hoff is a consultant for Spirita Oncology, LLC. Spirita Oncoloy, LLC provided funding for a portion of this study. The other authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}